Modulation of individual susceptibility to the no-reflow phenomenon after acute myocardial infarction

Current Pharmaceutical Design

Volumn 19, Issue 25, 2013, Pages 4519-4528

  Iwakura, Katsuomi ^a  

^a Sakurabashi Watanabe Hospital   (Japan)

Author keywords

Acute myocardial infarction; Embolization; Hyperglycemia; Inflammation; Ischemic preconditioning; Microcirculation; Statin

Indexed keywords

ABCIXIMAB; ADENOSINE; ANTIINFLAMMATORY AGENT; ATRIAL NATRIURETIC FACTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; NICORANDIL; TIROFIBAN;

ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR RISK; CARDIOVASCULAR THERAPEUTIC DEVICE; CORONARY REPERFUSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; ENDOTHELIUM CELL; GLUCOSE BLOOD LEVEL; HEART INFARCTION SIZE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; ISCHEMIC PRECONDITIONING; LEUKOCYTE ACTIVATION; MICROEMBOLISM; NO REFLOW PHENOMENON; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; REPERFUSION INJURY; THROMBOCYTE AGGREGATION; THROMBUS ASPIRATION;

ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION;

EID: 84881343494     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990327     Document Type: Article

References (123)

1. Piek JJ. Beyond epicardial reperfusion. N Engl J Med 2007; 356: 1880-2.
2. Gregorini L, Marco J, Kozàkovà M, et al. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation 1999; 99: 482-90.
3. Prasad A, Gersh BJ. Management of microvascular dysfunction and reperfusion injury. Heart 2005; 91: 1530-2.
4. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 1981; 304: 685-91.
5. Galiuto L, Lombardo A, Maseri A, et al. Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation. Heart 2003; 89: 731-7.
6. Galiuto L. Optimal therapeutic strategies in the setting of postinfarct no reflow: the need for a pathogenetic classification. Heart 2004; 90: 123-5.
7. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97: 765-72.
8. Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the 'no reflow' phenomenon. a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996; 93: 223-8.
9. Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute STsegment elevation myocardial infarction: a randomized controlled trial. JAMA 2005; 293: 1063-72.
10. Iwakura K, Ito H, Kawano S, et al. Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Coll Cardiol 2001; 38: 472-7.
11. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54: 1496-508.
12. Iwakura K, Ito H, Nishikawa N, et al. Early temporal changes in coronary flow velocity patterns in patients with acute myocardial infarction demonstrating the "no-reflow" phenomenon. Am J Cardiol 1999; 84: 415-9.
13. Turschner O, D'hooge J, Dommke C, et al. The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury. Eur Heart J 2004; 25: 794-803.
14. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1998; 32: 1312-9.
15. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006; 47: C13-8.
16. Limbruno U, Micheli A, De Carlo M, et al. Mechanical prevention of distal embolization during primary angioplasty: safety, feasibility, and impact on myocardial reperfusion. Circulation 2003; 108: 171-6.
17. Heusch G, Schulz R, Haude M, Erbel R. Coronary microembolization. J Mol Cell Cardiol 2004; 37: 23-31.
18. Sievert H, Wahr DW, Schuler G, et al. Effectiveness and safety of the proxis system in demonstrating retrograde coronary blood flow during proximal occlusion and in capturing embolic material. Am J Cardiol 2004; 94: 1134-9.
19. Quan V, Huynh R, Seifert PA, et al. Morphometric analysis of particulate debris extracted by four different embolic protection devices from coronary arteries, aortocoronary saphenous vein conduits, and carotid arteries. Am J Cardiol 2005; 95: 1415-9.
20. El-Jack SS, Suwatchai P, Stewart JT, et al. Distal embolization during native vessel and vein graft coronary intervention with a vascular protection device: predictors of high-risk lesions. J Interv Cardiol 2007; 20: 474-80.
21. Gössl M, von Birgelen C, Mintz GS, et al. Volumetric assessment of ulcerated ruptured coronary plaques with three-dimensional intravascular ultrasound in vivo. Am J Cardiol 2003; 91: 992-6, A7.
22. Napodano M, Ramondo A, Tarantini G, et al. Predictors and timerelated impact of distal embolization during primary angioplasty. Eur Heart J 2009; 30: 305-13.
23. Leineweber K, Böse D, Vogelsang M, Haude M, Erbel R, Heusch G. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. J Am Coll Cardiol 2006; 47: 981-6.
24. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009; 54: 281-92.
25. Reffelmann T, Kloner RA. The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol 2006; 101: 359-72.
26. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-35.
27. Takahashi T, Hiasa Y, Ohara Y, et al. Relation between neutrophil counts on admission, microvascular injury, and left ventricular functional recovery in patients with an anterior wall first acute myocardial infarction treated with primary coronary angioplasty. Am J Cardiol 2007; 100: 35-40.
28. Frink RJ, Rooney PAJ, Trowbridge JO, Rose JP. Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial infarction. Br Heart J 1988; 59: 196-200.
29. Engler RL, Schmid-Schönbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol 1983; 111: 98-111.
30. Ambrosio G, Tritto I. Reperfusion injury: experimental evidence and clinical implications. Am Heart J 1999; 138: S69-75.
31. Ito BR, Schmid-Schönbein G, Engler RL. Effects of leukocyte activation on myocardial vascular resistance. Blood Cells 1990; 16: 145-63.
32. Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the strategy study. J Am Coll Cardiol 2006; 48: 2178-85.
33. Lefer AM, Tsao P, Aoki N, Palladino MAJ. Mediation of cardioprotection by transforming growth factor-beta. Science 1990; 249: 61-4.
34. Furuichi K, Wada T, Iwata Y, et al. Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia-reperfusion injury. Crit Care Med 2006; 34: 2447-55.
35. Chamoun F, Burne M, O'Donnell M, Rabb H. Pathophysiologic role of selectins and their ligands in ischemia reperfusion injury. Front Biosci 2000; 5: E103-9.
36. Zweier JL, Talukder MAH. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 2006; 70: 181-90.
37. Carden DL, Granger DN. Pathophysiology of ischaemiareperfusion injury. J Pathol 2000; 190: 255-66.
38. Matsumoto H, Inoue N, Takaoka H, et al. Depletion of antioxidants is associated with no-reflow phenomenon in acute myocardial infarction. Clin Cardiol 2004; 27: 466-70.
39. Ambrosio G, Weisman HF, Mannisi JA, Becker LC. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation 1989; 80: 1846-61.
40. Pinsky DJ, Naka Y, Liao H, Oz MC, Wagner DD, Mayadas TN, et al. Hypoxia-induced exocytosis of endothelial cell weibel-palade bodies. a mechanism for rapid neutrophil recruitment after cardiac preservation. J Clin Invest 1996; 97: 493-500.
41. Oswald GA, Smith CC, Betteridge DJ, Yudkin JS. Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction. Br Med J (Clin Res Ed) 1986; 293: 917-22.
42. Oswald GA, Yudkin JS. Hyperglycaemia following acute myocardial infarction: the contribution of undiagnosed diabetes. Diabet Med 1987; 4: 68-70.
43. Sewdarsen M, Jialal I, Vythilingum S, Govender G, Rajput MC. Stress hyperglycaemia is a predictor of abnormal glucose tolerance in indian patients with acute myocardial infarction. Diabetes Res 1987; 6: 47-9.
44. Tansey MJ, Opie LH. Plasma glucose on admission to hospital as a metabolic index of the severity of acute myocardial infarction. Can J Cardiol 1986; 2: 326-31.
45. Oswald GA, Corcoran S, Yudkin JS. Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet 1984; 1: 1264-7.
46. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000; 355: 773-8.
47. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström Aet al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
48. Bolk J, van der Ploeg T, Cornel JH, Arnold AE, Sepers J, Umans VA. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol 2001; 79: 207-14.
49. Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano Ket al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003; 41: 1-7.
50. Ceriello A. Acute hyperglycaemia: a 'new' risk factor during myocardial infarction. Eur Heart J 2005; 26: 328-31.
51. Smit JWA, Romijn JA. Acute insulin resistance in myocardial ischemia: causes and consequences. Semin Cardiothorac Vasc Anesth 2006; 10: 215-9.
52. Prasad A, Stone GW, Stuckey TD, Costantini CO, Zimetbaum PJ, McLaughlin M, et al. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J Am Coll Cardiol 2005; 45: 508-14.
53. Ottani F, Galvani M, Ferrini D, Sorbello F, Limonetti P, Pantoli D, et al. Prodromal angina limits infarct size. a role for ischemic preconditioning. Circulation 1995; 91: 291-7.
54. Rezkalla SH, Kloner RA. Ischemic preconditioning and preinfarction angina in the clinical arena. Nat Clin Pract Cardiovasc Med 2004; 1: 96-102.
55. Kaeffer N, Richard V, François A, Lallemand F, Henry JP, Thuillez C. Preconditioning prevents chronic reperfusion-induced coronary endothelial dysfunction in rats. Am J Physiol 1996; 271: H842-9.
56. Richard V, Kaeffer N, Tron C, Thuillez C. Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion. Circulation 1994; 89: 1254-61.
57. Beauchamp P, Richard V, Tamion F, Lallemand F, Lebreton JP, Vaudry Het al. Protective effects of preconditioning in cultured rat endothelial cells: effects on neutrophil adhesion and expression of icam-1 after anoxia and reoxygenation. Circulation 1999; 100: 541-6.
58. Kubes P, Payne D, Ostrovsky L. Preconditioning and adenosine in i/r-induced leukocyte-endothelial cell interactions. Am J Physiol 1998; 274: H1230-8.
59. Akimitsu T, Gute DC, Korthuis RJ. Ischemic preconditioning attenuates postischemic leukocyte adhesion and emigration. Am J Physiol 1996; 271: H2052-9.
60. Dirksen MT, Laarman GJ, Simoons ML, Duncker DJGM. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res 2007; 74: 343-55.
61. Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DEet al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002; 105: 1285-90.
62. Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 2003; 108: 548-53.
63. Halkin A, Masud AZ, Rogers C, Hermiller J, Feldman R, Hall P, et al. Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the fire trial. Am Heart J 2006; 151: 915. e1-7.
64. Swaminathan A, Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, et al. Influence of vessel diameter on the efficacy of distal protection devices during saphenous vein graft intervention. Am J Cardiol 2005; 95: 651-4.
65. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions. the task force for percutaneous coronary interventions of the european society of cardiology. Eur Heart J 2005; 26: 804-47.
66. Gick M, Jander N, Bestehorn H, Kienzle R, Ferenc M, Werner K, et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation 2005; 112: 1462-9.
67. Cura FA, Escudero AG, Berrocal D, Mendiz O, Trivi MS, Fernandez J, et al. Protection of distal embolization in high-risk patients with acute ST-segment elevation myocardial infarction (PREMIAR). Am J Cardiol 2007; 99: 357-63.
68. Kelbaek H, Terkelsen CJ, Helqvist S, Lassen JF, Clemmensen P, Kløvgaard L, et al. Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trial. J Am Coll Cardiol 2008; 51: 899-905.
69. West NEJ, Hoole SP, McCormick L. Are all distal protection devices created equal?. J Am Coll Cardiol 2010; 56: 745-6.
70. Kaltoft A, Kelbaek H, Kløvgaard L, Terkelsen CJ, Clemmensen P, Helqvist S, et al. Increased rate of stent thrombosis and target lesion revascularization after filter protection in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: 15-month follow-up of the DEDICATION (Drug Elution and Distal Protection in ST Elevation Myocardial Infarction) trial. J Am Coll Cardiol 2010; 55: 867-71.
71. Svilaas T, Vlaar PJ, van der Horst IC, Diercks GFH, de Smet BJGL, van den Heuvel AFM, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008; 358: 557-67.
72. Vlaar PJ, Svilaas T, van der Horst IC, Diercks GFH, Fokkema ML, de Smet BJGL, et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet 2008; 371: 1915-20.
73. Amin AP, Mamtani MR, Kulkarni H. Factors influencing the benefit of adjunctive devices during percutaneous coronary intervention in ST-segment elevation myocardial infarction: meta-analysis and meta-regression. J Interv Cardiol 2009; 22: 49-60.
74. De Luca G, Dudek D, Sardella G, Marino P, Chevalier B, Zijlstra F. Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. Eur Heart J 2008; 29: 3002-10.
75. Iwakura K, Ito H, Kawano S, Okamura A, Kurotobi T, Date M, et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 2006; 27: 534-9.
76. Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002; 97: 105-16.
77. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003; 41: 508-15.
78. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 2003; 35: 339-41.
79. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359: 473-81.
80. Litt MR, Jeremy RW, Weisman HF, Winkelstein JA, Becker LC. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. evidence for neutrophilmediated reperfusion injury. Circulation 1989; 80: 1816-27.
81. Hayward R, Campbell B, Shin YK, Scalia R, Lefer AM. Recombinant soluble p-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovasc Res 1999; 41: 65-76.
82. Ma XL, Tsao PS, Lefer AM. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest 1991; 88: 1237-43.
83. Horwitz LD, Kaufman D, Kong Y. An antibody to leukocyte integrins attenuates coronary vascular injury due to ischemia and reperfusion in dogs. Am J Physiol 1997; 272: H618-24.
84. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998; 97: 2259-67.
85. Zhao ZQ, Lefer DJ, Sato H, Hart KK, Jefforda PR, Vinten-Johansen J. Monoclonal antibody to ICAM-1 preserves postischemic blood flow and reduces infarct size after ischemiareperfusion in rabbit. J Leukoc Biol 1997; 62: 292-300.
86. Faxon DP, Gibbons RJ, Chronos NAF, Gurbel PA, Sheehan F. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol 2002; 40: 1199-204.
87. Baran KW, Nguyen M, McKendall GR, Lambrew CT, Dykstra G, Palmeri ST, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 2001; 104: 2778-83.
88. Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003; 108: 1176-83.
89. Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108: 1184-90.
90. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes DJ, O'Neill WW, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007; 297: 43-51.
91. Forman MB, Stone GW, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev 2006; 24: 116-47.
92. Forman MB, Jackson EK. Importance of tissue perfusion in st segment elevation myocardial infarction patients undergoing reperfusion strategies: role of adenosine. Clin Cardiol 2007; 30: 583-5.
93. Sdringola S, Assali A, Ghani M, Yepes A, Rosales O, Schroth GW, et al. Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc Interv 2000; 51: 394-9.
94. Fischell TA, Carter AJ, Foster MT, Hempsall K, DeVries J, Kim DH, et al. Reversal of "no reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998; 45: 360-5.
95. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation 2000; 101: 2154-9.
96. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999; 34: 1711-20.
97. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005; 45: 1775-80.
98. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007; 370: 1483-93.
99. Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 2008; 117: 3152-6.
100. Kevelaitis E, Oubénaïssa A, Peynet J, Mouas C, Menasché P. Preconditioning by mitochondrial ATP-sensitive potassium channel openers: an effective approach for improving the preservation of heart transplants. Circulation 1999; 100: II345-50.
101. Mizumura T, Nithipatikom K, Gross GJ. Bimakalim, an ATPsensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs. Circulation 1995; 92: 1236-45.
102. Yao Z, Gross GJ. Activation of ATP-sensitive potassium channels lowers threshold for ischemic preconditioning in dogs. Am J Physiol 1994; 267: H1888-94.
103. Matsuda N, Morgan KG, Sellke FW. Preconditioning improves cardioplegia-related coronary microvascular smooth muscle hypercontractility: role of KATP channels. J Thorac Cardiovasc Surg 1999; 118: 438-45.
104. Ren Z, Yang Q, Floten HS, Furnary AP, Yim AP, He GW. ATPsensitive potassium channel openers may mimic the effects of hypoxic preconditioning on the coronary artery. Ann Thorac Surg 2001; 71: 642-7.
105. Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33: 654-60.
106. Sugimoto K, Ito H, Iwakura K, Ikushima M, Kato A, Kimura R, et al. Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. Circ J 2003; 67: 295-300.
107. Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005; 112: 1284-8.
108. Iwakura K, Ito H, Okamura A, Koyama Y, Date M, Higuchi Y, et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J 2009; 73: 925-31.
109. Kunichika H, Ben-Yehuda O, Lafitte S, Kunichika N, Peters B, DeMaria AN. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. a quantitative myocardial contrast echocardiography study. J Am Coll Cardiol 2004; 43: 276-83.
110. Yang Y, Zhao J, You S, Wu Y, Jing Z, Yang W, et al. Different effects of tirofiban and aspirin plus clopidogrel on myocardial noreflow in a mini-swine model of acute myocardial infarction and reperfusion. Heart 2006; 92: 1131-7.
111. Yip H, Wu C, Chang H, Hsieh Y, Fang C, Chen S, et al. Impact of tirofiban on angiographic morphologic features of high-burden thrombus formation during direct percutaneous coronary intervention and short-term outcomes. Chest 2003; 124: 962-8.
112. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-94.
113. Mehta SR, Yusuf S, Díaz R, Zhu J, Pais P, Xavier D, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATEECLA randomized controlled trial. JAMA 2005; 293: 437-46.
114. Díaz R, Goyal A, Mehta SR, Afzal R, Xavier D, Pais P, et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA 2007; 298: 2399-405.
115. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004; 61: 448-60.
116. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993; 87: 893-9.
117. Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD. Myocardial protection by brief ischemia in noncardiac tissue. Circulation 1996; 94: 2193-200.
118. Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation 1997; 96: 1641-6.
119. Bøtker HE, Kharbanda R, Schmidt MR, Bøttcher M, Kaltoft AK, Terkelsen CJ, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010; 375: 727-34.
120. Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol 2010; 55: 2383-9.
121. Sasano T, McDonald AD, Kikuchi K, Donahue JK. Molecular ablation of ventricular tachycardia after myocardial infarction. Nat Med 2006; 12: 1256-8.
122. Hu D, Viskin S, Oliva A, Carrier T, Cordeiro JM, Barajas-Martinez H, et al. Novel mutation in the SCN5A gene associated with arrhythmic storm development during acute myocardial infarction. Heart Rhythm 2007; 4: 1072-80.
123. Zalewski J, Undas A, Godlewski J, Stepien E, Zmudka K. Noreflow phenomenon after acute myocardial infarction is associated with reduced clot permeability and susceptibility to lysis. Arterioscler Thromb Vasc Biol 2007; 27: 2258-65.